当前位置: 首页 > 期刊 > 《中国现代医生》 > 2019年第32期
编号:13440124
子宫腺肌病实施子宫切除术前用米非司酮预处理的临床分析(4)
http://www.100md.com 2019年11月15日 《中国现代医生》 2019年第32期
     [11] Gerhard Leyendecker,LudwigWildt.A new concept of endometriosis and adenomyosis:Tissue injury and repair (TIAR)[J]. Hormone Molecular Biology and Clinical Investigation, 2011,5(2):125-142.

    [12] 冷金花.子宫腺肌病诊治中存在的问題[J].中国实用妇科与产科杂志,2019,35(5):489-492.

    [13] Vannuccini S,Luisi S,Tosti C,et al.Role of medical therapy inthe management of uterine adenomyosis[J].FertilSteril,2018,109(3):398-405.

    [14] Hisao Osada. Uterine adenomyosis and adenomyoma:The surgical approach[J]. Fertility and Sterility,2018,109(3):406-417.

    [15] 冯定庆,凌斌.子宫腺肌病术后长期管理策略[J].中国实用妇科与产科杂志,2017,33(2):154-157.

    [16] Kim SM,Park EK,Jeung IC,et al. Abdominal,multiport andsingle-port total laparoscopic hysterectomy:Elevenyear trendscomparison of surgical outcomes complications of 936 cases[J]. Arch Gynecol Obstet,2015,291(6):1313-1319.

    [17] Michelle Louie,Paula D. Strassle,Janelle K,Moulder,et al.Uterine weight and complications after abdominal,laparoscopic,and vaginal hysterectomy[J]. American Journal of Obstetrics and Gynecology,2018,219(5):e1-e8.

    [18] 王晓雨.不同剂量米非司酮治疗子宫肌瘤效果比较[J].中国实用医药,2019,14(8):104-106.

    [19] Mahajan DK,London SN. Mifepristone(RU486):A review[J]. Fertility and Sterility,1997,68(6):967-976.

    [20] 姬化革.他莫昔芬联合米非司酮治疗围绝经期子宫肌瘤的疗效观察[J].中国妇幼保健,2017,32(20):4929-4932.

    [21] 刘丹秋,汪期明.子宫肌瘤药物治疗的现状及进展[J].现代实用医学,2018,30(7):844-847.

    (收稿日期:2019-06-21), http://www.100md.com(邱衎 淮丽 王丹菡)
上一页1 2 3 4